Sign in

CIK 0001651308

  • Large accelerated filer

BeOne Medicines Ltd.

Sign in to watch
Ticker
BEIGF
Exchange
Nasdaq, OTC
Industry
Pharmaceutical Preparations
FY end
Dec 31
Entity type
Operating
EIN
981209416
Phone
+41 616851900
Business address
C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
Former names
BeiGene, Ltd.

Securities

  • ONC American Depositary Shares Nasdaq
  • BEIGF Common stock OTC
  1. 4 Derivatives Options or other derivatives
  2. 4 Open-market sale Director sold 41,463 shares at an average $30.66 ($1,271,175)
  3. 4 Open-market sale Director sold 47,149 shares at an average $29.61 ($1,395,992)
  4. 4 Open-market sale Director sold 36,443 shares at an average $31.02 ($1,130,355)
  5. 4 Open-market sale Director sold 67,252 shares at an average $31.42 ($2,113,061)
  6. 4 Grant or award CMO, Hematology acquired 300,000 shares (grant or award)
  7. 3 Insider Initial Statement of Ownership
  8. 4 Grant or award CMO, Immuno-oncology acquired 300,000 shares (grant or award)
  9. 3 Insider Initial Statement of Ownership
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Grant or award EVP and Gl. Head of Bus. Dev. acquired 475,000 shares (grant or award)
  14. 3 Insider Initial Statement of Ownership
  15. 4 Open-market buy 10% owner bought 9,100,000 shares
  16. 4 Conversion 10% owner acquired 23,646,724 shares (conversion)
  17. 4 Conversion CEO acquired 9,398,380 shares (conversion)
  18. 4 Derivatives Options or other derivatives
  19. 4 Open-market buy CFO & Chief Strategy Officer bought 65,000 shares at $1.85 ($120,250)
  20. 4 Open-market buy Chief Medical Officer bought 130,000 shares at $1.85 ($240,500)

Page 28 of 29 · 580 filings